통증 관리약 시장 : 약제 클래스별, 유통경로별, 지역별

Pain Management Drugs Market is estimated to be valued at USD 88.4 Bn in 2026 and is expected to reach USD 113.15 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.6% from 2026 to 2033.

Pain management medications are specific drug classes, which have pharmacological actions on pain receptors and work against the pain symptoms. These medications include opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, muscle relaxants, and others. These medications can be used for pain management of conditions, as indicated on label and some medications have off-label uses. For instance, anticonvulsants and antidepressants were originally used for the management of epilepsy and depression respectively. However, these medications have shown activity against pain indications and are prescribed for pain management as off-label indication. Moreover, opioids are majorly prescribed for the management of acute as well as chronic pain. This has also resulted in self-medication by patients, resulting in misuse or overdose of opioid containing drug products. Moreover, majority of the drugs have lost patent protection over the years and generic versions of the same are widely available in the market. Commercially available pain management drugs include Fentanyl, Hydromorphone, Oxycodone, Aspirin, Diazepam, and others.

Market Dynamics

The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. For instance, in February 2018, according to data published by National Center for Biotechnology Information, increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.

Key features of the study

• This report provides an in-depth analysis of the global pain management drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pain management drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pain management drugs market

Market Segmentation

• Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
  • Opioids
  • NSAIDs
  • Anticonvulsants
  • Antidepressants
  • Others
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Pfizer, Inc.
  • Sanofi S.A.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Eily, Lilly, and Company
  • Abbott Laboratories
  • Purdue Pharma L.P.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • F. Hoffmann La Roche Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Pain Management Drugs Market, By Drug Class
  • Global Pain Management Drugs Market, By Distribution Channel
  • Global Pain Management Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Pain Management Drugs Market, By Drug Class, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• NSAIDs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Pain Management Drugs Market, By Distribution Channel, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Pain Management Drugs Market, By Region, 2020 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eily, Lilly, and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Purdue Pharma L.P.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline Plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

8. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

9. References and Research Methodology

• References
• Research Methodology
• About us